Search research articles
Contact Us
Filters
Showing results (71-80 of 89) with videos related to
Page
of 9
Sort By:
The Journal of Clinical Investigation
|
December 16, 2004
Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy
Jonathan D Silk, Ian F Hermans, Uzi Gileadi, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
November 11, 2003
High avidity antigen-specific CTL identified by CD8-independent tetramer staining
Ed Man-Lik Choi, Ji-Li Chen, Linda Wooldridge, et al.
Chemical Science
|
July 19, 2017
NKT cell-dependent glycolipid-peptide vaccines with potent anti-tumour activity
Regan J Anderson, Benjamin J Compton, Ching-Wen Tang, et al.
Allergy
|
June 29, 2021
MR1-dependent immune surveillance of the skin contributes to pathogenesis and is a photobiological target of UV light therapy in a mouse model of atopic dermatitis
Karmella Naidoo, Katherine Woods, Christophe Pellefigues, et al.
RSC Chemical Biology
|
June 3, 2022
6″-Modifed α-GalCer-peptide conjugate vaccine candidates protect against liver-stage malaria
Michael A Meijlink, Yu Cheng Chua, Susanna T S Chan, et al.
Nature Chemical Biology
|
October 6, 2014
A self-adjuvanting vaccine induces cytotoxic T lymphocytes that suppress allergy
Regan J Anderson, Ching-wen Tang, Naomi J Daniels, et al.
Clinical & Translational Immunology
|
July 7, 2022
Glycolipid-peptide conjugate vaccines elicit CD8<sup>+</sup> T-cell responses and prevent breast cancer metastasis
Olivia K Burn, Kathryn Farrand, Tara Pritchard, et al.
Oncoimmunology
|
June 17, 2022
Intratumoural administration of an NKT cell agonist with CpG promotes NKT cell infiltration associated with an enhanced antitumour response and abscopal effect
Kef K Prasit, Laura Ferrer-Font, Olivia K Burn, et al.
Journal for Immunotherapy of Cancer
|
April 17, 2024
Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma
Florian Hornsteiner, Janine Vierthaler, Helen Strandt, et al.
Cancer Immunology, Immunotherapy : CII
|
November 3, 2017
A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients
Olivier Gasser, Katrina J Sharples, Catherine Barrow, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 89) with videos related to
Sort By:
Page
of 9
The Journal of Clinical Investigation
|
December 16, 2004
Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy
Jonathan D Silk, Ian F Hermans, Uzi Gileadi, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
November 11, 2003
High avidity antigen-specific CTL identified by CD8-independent tetramer staining
Ed Man-Lik Choi, Ji-Li Chen, Linda Wooldridge, et al.
Chemical Science
|
July 19, 2017
NKT cell-dependent glycolipid-peptide vaccines with potent anti-tumour activity
Regan J Anderson, Benjamin J Compton, Ching-Wen Tang, et al.
Allergy
|
June 29, 2021
MR1-dependent immune surveillance of the skin contributes to pathogenesis and is a photobiological target of UV light therapy in a mouse model of atopic dermatitis
Karmella Naidoo, Katherine Woods, Christophe Pellefigues, et al.
RSC Chemical Biology
|
June 3, 2022
6″-Modifed α-GalCer-peptide conjugate vaccine candidates protect against liver-stage malaria
Michael A Meijlink, Yu Cheng Chua, Susanna T S Chan, et al.
Nature Chemical Biology
|
October 6, 2014
A self-adjuvanting vaccine induces cytotoxic T lymphocytes that suppress allergy
Regan J Anderson, Ching-wen Tang, Naomi J Daniels, et al.
Clinical & Translational Immunology
|
July 7, 2022
Glycolipid-peptide conjugate vaccines elicit CD8<sup>+</sup> T-cell responses and prevent breast cancer metastasis
Olivia K Burn, Kathryn Farrand, Tara Pritchard, et al.
Oncoimmunology
|
June 17, 2022
Intratumoural administration of an NKT cell agonist with CpG promotes NKT cell infiltration associated with an enhanced antitumour response and abscopal effect
Kef K Prasit, Laura Ferrer-Font, Olivia K Burn, et al.
Journal for Immunotherapy of Cancer
|
April 17, 2024
Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma
Florian Hornsteiner, Janine Vierthaler, Helen Strandt, et al.
Cancer Immunology, Immunotherapy : CII
|
November 3, 2017
A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients
Olivier Gasser, Katrina J Sharples, Catherine Barrow, et al.
Page
of 9